Integrated Viral Hepatitis Surveillance, Testing, Treatment, and Prevention Programs for Health Departments (IVH-STTP)

The Integrated Viral Hepatitis Surveillance, Testing, Treatment, and Prevention Programs for Health Departments opportunity is a federal funding initiative administered by the Centers for Disease Control and Prevention within the U.S. Department of Health and Human Services. This program is designed to strengthen public health infrastructure and advance national efforts to eliminate viral hepatitis across the United States and its territories. The CDC, through its National Center for HIV, Viral Hepatitis, STD, and TB Prevention, plays a central role in coordinating disease surveillance and prevention strategies, and this funding opportunity reflects its continued commitment to improving population health outcomes through coordinated, data-driven interventions. The primary purpose of this opportunity is to support integrated programs that combine surveillance, outbreak response, testing, treatment, and prevention of viral hepatitis. The scope includes hepatitis A, hepatitis B (acute and chronic), and hepatitis C (acute, chronic, and perinatal). Funded activities are expected to enhance the ability of health departments to detect, monitor, and respond to viral hepatitis cases through improved data systems, disease registries, and analytic capabilities. The program also emphasizes the use of data to inform interventions and improve public health decision-making, particularly through data-to-care strategies that connect diagnosed individuals with treatment and services. Funding supports both required and optional program components. Required components include outbreak response and surveillance, as well as planning, partnerships, and promotion. Optional components allow applicants to expand into testing, treatment, and prevention initiatives, as well as develop programs targeting perinatal hepatitis C. Allowable uses of funds include strengthening surveillance infrastructure, expanding testing and treatment access in high-impact settings, developing partnerships, and enhancing coordination across healthcare and community systems. There is no cost sharing or matching requirement, which lowers financial barriers for eligible public health entities. Eligibility is limited to governmental public health entities and their bona fide agents. This includes all 50 state health departments, the District of Columbia, U.S. territories, and local health agencies. In cases where cities lack independent public health departments, county-level agencies may apply on their behalf. Bona fide agents must provide documentation demonstrating their formal relationship with an eligible entity. This structure ensures that funding is directed to organizations with the authority and capacity to implement large-scale public health programs. The application process is expected to be conducted electronically, with submissions due by the specified deadline through appropriate federal systems. While detailed application components are not fully outlined in the forecast notice, applicants can expect to provide program plans, budgets, and supporting documentation demonstrating their capacity to carry out the required and optional components. Evaluation criteria will likely focus on program design, capacity, alignment with CDC priorities, and the ability to achieve measurable public health outcomes. The timeline indicates that this is a forecasted opportunity, with an estimated posting date in October 2026 and an application deadline in December 2026. Awards are expected to be made in April 2027, with project activities beginning in May 2027. The total estimated program funding is substantial, indicating a large-scale, multi-award initiative intended to support widespread national impact. The opportunity does not explicitly state recurrence, but similar CDC cooperative agreements are often reissued periodically. For additional information, applicants may contact the CDC program representative via email or phone as provided in the notice.